Blog

Katy Beckermann: Feasibility of an intermittent ipi/nivo approach in their Phase II trial

Photo taken from medschool.vanderbilt.edu

Aug 30, 2024, 16:32

Katy Beckermann: Feasibility of an intermittent ipi/nivo approach in their Phase II trial

Katy Beckermann, Assistant Professor Of Medicine, Vanderbilt University Medical Center, shared a post on X:

“Congrats to Moshe Ornstein, MD and team for demonstrating the feasibility of an intermittent ipi/nivo approach in their Phase II trial, showing potential for prolonged treatment-free intervals. Looking forward to more studies like this.”

Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Front-line Ipilimumab and Nivolumab

Authors: Moshe C. Ornstein, Laeth George, Wei Wei, C. Marcela Diaz-Montero, Pat Rayman, Allison Martin, Arnab Basu, Kathryn E.

Beckermann, Amanda Nizam, Christopher E. Wee, Timothy D. Gilligan, Shilpa Gupta, Brian I. Rini

Additional information
Source: Katy Beckermann/X

Academic clinical trials Allison Martin Amanda Nizam Arnab Basu Brian I. Rini C. Marcela Diaz-Montero cancer Christopher E. Wee Kathryn E. Beckermann Katy Beckermann Laeth George Moshe C. Ornstein Moshe Ornstein OncoDaily Oncology Pat Rayman Shilpa Gupta Timothy D. Gilligan Vanderbilt University Medical Center Wei Wei

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer